Melatonin Plus
Melatonin Plus, licence 80046644: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Lorna Vanderhaeghe Health Solutions a division of Jamieson Laboratories Ltd
- NPN or DIN-HM
- 80046644
- Status
- Inactive licence
- Licence date
- 28 November 2013
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Microcrystalline cellulose, Saveur de menthe poivrée, Lactose monohydrate, Croscarmellose de sodium, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Comprimé | 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule, e.g. shift-work and jet lag. Helps to prevent and/or reduce the effects of jet lag (e.g. daytime fatigue, sleep disturbance) for people travelling by plane easterly across two or more time zones. Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circulation rhythm).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80046644
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.